¼¼°èÀÇ ½Å°æ³»°ú¿ë »öÀü ±â±â ½ÃÀå
Embolization Devices for Neurology
»óǰÄÚµå : 1795908
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 475 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,209,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,629,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½Å°æ³»°ú¿ë »öÀü ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 18¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Å°æ³»°ú¿ë »öÀü ±â±â ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 2.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 18¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ »öÀü ÄÚÀÏÀº CAGR 3.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 9,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾×ü »öÀü ½Ã½ºÅÛ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 1.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 2,440¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 4.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Å°æ³»°ú¿ë »öÀü ±â±â ½ÃÀåÀº 2024³â¿¡ 4¾ï 2,440¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 4.9%·Î 2030³â±îÁö 3¾ï 4,870¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 0.8%¿Í 1.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ½Å°æ³»°ú¿ë »öÀü ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

³ú»öÀü¼ú ±â±â´Â ½Å°æÇÐÀû °³ÀÔ¿¡ ¾î¶² Çõ¸íÀ» °¡Á®¿À°í Àִ°¡?

³ú»öÀü¼úÀº ³úµ¿¸Æ·ù, µ¿Á¤¸Æ±âÇü(AVM), Á¾¾ç µî º¹ÀâÇÑ ½Å°æÁúȯÀÇ Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ ±â±¸µéÀº ºñÁ¤»óÀûÀÎ Ç÷°üÀ» ÀǵµÀûÀ¸·Î ¸·°Å³ª ȯºÎ·Î °¡´Â Ç÷·ù¸¦ °¨¼Ò½ÃÄÑ ÆÄ¿­À̳ª ÃâÇ÷ÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. ½Å°æ°ú¿¡¼­ »öÀü¼úÀº Á¾Á¾ ¼ö¼ú Àü º¸Á¶ ¶Ç´Â ´Üµ¶ÀÇ ÃÖ¼Òħ½ÀÀû ½Ã¼ú·Î »ç¿ëµË´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀ¸·Î »öÀü¼úÀº °³µÎ ¼ö¼ú¿¡ µû¸¥ À§ÇèÀ» ÇÇÇÒ ¼ö ÀÖ´Â Çö½ÇÀûÀ̰í Ç¥ÀûÈ­µÈ ÇØ°áÃ¥ÀÌ µÇ¾ú½À´Ï´Ù.

³úµ¿¸Æ·ù¿Í ³úÁ¹ÁßÀÇ À¯º´·ü Áõ°¡´Â ½Å°æÇ÷°ü »öÀü¼úÀÇ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¿µ»ó Áø´Ü, Ä«Å×ÅÍ Ä¡·á, ¸¶ÀÌÅ©·Î ÄÚÀÏ ¼³°èÀÇ ¹ßÀüÀ¸·Î ÀÇ»ç´Â ÀÌÀü¿¡´Â ¼ö¼úÀÌ ºÒ°¡´ÉÇß´ø Ç÷°ü ÀÌ»óÀ» º¸´Ù Á¤È®ÇÏ°Ô Ä¡·áÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ½Ç½Ã°£ ³»ºñ°ÔÀ̼ǰú ÀÛ°í À¯¿¬ÇÑ Àü´Þ ½Ã½ºÅÛÀÇ »ç¿ëÀ¸·Î ȯÀÚ ¿¹Èİ¡ °³¼±µÇ°í ÇÕº´Áõ ¹ß»ý·üÀÌ °¨¼ÒÇß½À´Ï´Ù. »öÀü¼úÀº ƯÈ÷ ¿Ü°úÀû Á¢±ÙÀÌ ¾î·Á¿î °æ¿ì, ƯÁ¤ Ç÷°ü Á¾¾çÀ̳ª ÃâÇ÷¼º ³úÁ¹Áß »óŸ¦ °ü¸®ÇÏ´Â µ¥¿¡µµ ÀûÇÕÇÑ ¹æ¹ýÀÔ´Ï´Ù.

¾î¶² Çõ½ÅÀÌ »öÀü¼ú ±â±âÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀ̰í Àִ°¡?

ÇÏÀ̵å·Î°Ö ÄÚÆÃ ÄÚÀÏ, Å»Âø½Ä dz¼±, ¾×ü »öÀüÁ¦ µî »öÀüÁ¦ÀÇ Àç·á Çõ½ÅÀº Ç÷°ü Æó»öÀÇ Á¤È®¼º°ú Áö¼Ó¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ Àç·áµéÀº »ýüÀûÇÕ¼ºÀ» À¯ÁöÇϸ鼭 º¹ÀâÇÑ Ç÷°ü ÇüÅ¿¡ ¸Â°Ô ¼³°èµÇ¾î À̵¿ ¶Ç´Â Àç°üÅëÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î ±â±â Áß ÀϺδ ¹Ú¸® ¹× È®ÀåÀ» Á¦¾îÇÒ ¼ö ÀÖ¾î ¼¶¼¼ÇÑ ³ú ºÎÀ§¿¡¼­ º¸´Ù Á¤¹ÐÇÑ Àü°³°¡ °¡´ÉÇÕ´Ï´Ù. Ç÷·ùÀüȯ ½ºÅÙÆ®³ª ¼¼Æ÷ ³» Ç÷·ù±³¶õ±â±âÀÇ µîÀåÀ¸·Î ±âÁ¸ ÄÚÀÏÀ» ÀÌ¿ëÇÑ Ä¡·á¹ýº¸´Ù »öÀü¼úÀÇ Ä¡·á ¿µ¿ªÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

Ä«Å×ÅÍ ±â¼úÀÇ Çâ»óÀ¸·Î ±¼°îÁø ³úÇ÷°ü ³»¸¦ º¸´Ù ¾ÈÁ¤ÀûÀ¸·Î ÃßÀûÇÒ ¼ö ÀÖ´Â ³»ºñ°ÔÀ̼ÇÀÌ °¡´ÉÇØÁö°í ÀÖ½À´Ï´Ù. ½ºÆ¼¾î·¯ºí ¸¶ÀÌÅ©·ÎÄ«Å×ÅÍ, ÄÚÆÃµÈ °¡À̵å¿ÍÀ̾î, ·Î¿ì ÇÁ·ÎÆÄÀÏ Àü´Þ ½Ã½ºÅÛÀº ±â±â »ðÀÔÀÇ Á¤È®¼º°ú ½Ã¼ú È¿À²À» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ƯÈ÷ º¹ÀâÇÑ ½Å°æÇ÷°ü »ç·Ê³ª »Ñ¸® ±íÀº ½Å°æÇ÷°ü »ç·Ê¿¡¼­ Ç÷°ü ¿Ü»ó À§ÇèÀ» ÁÙÀÌ°í ½Ã¼ú ¼º°ø·üÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¿µ»ó Áø´Ü ½Ã½ºÅÛÀÌ °³¼±µÇ¸é¼­ »öÀü¼ú°úÀÇ ÅëÇÕÀ» ÅëÇØ ´õ ³ªÀº Ä¡·á °èȹ, ¼ö¼ú Áß Æò°¡, Ä¡·á ÈÄ °æ°ú °üÂûÀÌ °¡´ÉÇØÁ³½À´Ï´Ù.

¾î¶² ÇコÄɾî ȯ°æ°ú ½Å°æÁúȯÀÌ ¼ö¿ä¸¦ °ßÀÎÇϰí Àִ°¡?

½Å°æÇ÷°ü»öÀü¼úÀº ÷´Ü ¿µ»ó Áø´Ü, ½Å°æÁßÀç Àü¹®ÆÀ, ÁýÁßÄ¡·á ÀÎÇÁ¶ó¸¦ °®Ãá 3Â÷ ÀÇ·á±â°ü°ú ³úÁ¹Áß¼¾ÅͰ¡ ¿©ÀüÈ÷ ÁÖ¿ä Ä¡·á ȯ°æÀ¸·Î ²ÅÈ÷°í ÀÖ½À´Ï´Ù. °¡Àå ¸¹ÀÌ Ä¡·áÇÏ´Â ÁúȯÀº µÎ°³³» µ¿¸Æ·ù, AVM, ÃâÇ÷¼º ³úÁ¹Áß µîÀÔ´Ï´Ù. »öÀü¼úÀº ¼ö¸·Á¾°ú °°Àº Ç÷°üÁ¾¾ç °ü¸®¿Í ½Å°æ¿Ü°ú ¼ö¼ú Áß ¼ö¼ú Áß ÃâÇ÷À» ÁÙÀ̱â À§ÇØ »ç¿ëµÇ±âµµ ÇÕ´Ï´Ù. ºñħ½ÀÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, ±âº»ÀûÀÎ ÁßÀçÀû ¿µ»óÀÇÇÐÀ» °®Ãá 2Â÷ ÀÇ·á ÇöÀå¿¡¼­µµ ÀÌ·¯ÇÑ ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÀ±Þ ½Å°æÇÐ, ƯÈ÷ ±Þ¼º ÃâÇ÷¼º Áúȯ¿¡¼­ »öÀü¼úÀÇ »ç¿ëÀÌ È®´ëµÊ¿¡ µû¶ó ½Å¼ÓÇϰí È¿À²ÀûÀÎ ±â±â ½Ã½ºÅÛÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ½Å°æÇÐ ¹× ³úÁ¹Áß ÀÇ·Ú ³×Æ®¿öÅ©´Â ¼Ò±Ô¸ð ¼¾ÅͰ¡ ÷´Ü ÁßÀç½Ã¼ú Àåºñ¿Í ¿¬°áµÉ ¼ö ÀÖµµ·Ï µµ¿Í ½Ã¼ú °Ç¼ö¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø´Ü °Ë»ç°¡ °³¼±µÇ°í ¿ì¹ßÀû µ¿¸Æ·ù ¹ß°ßÀ²ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼±Á¦Àû »öÀü¼úÀ» ¹Þ´Â ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÀ±Þ ¹× ´ë±â Ä¡·á °Ç¼öÀÇ Áõ°¡´Â ½ÃÀåÀÇ ¼ºÀå ±â¹ÝÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

½Å°æ°ú¿ë »öÀü ±â±â ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

½Å°æ°ú¿ë »öÀü ±â±â ½ÃÀåÀÇ ¼ºÀåÀº Áúº´ÀÇ À¯Çà, ±â±âÀÇ Á¤È®¼º, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¿Í °ü·ÃµÈ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù. ³úµ¿¸Æ·ù, AVM, ÃâÇ÷¼º ³úÁ¹ÁßÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ç¥Àû Ç÷°üÆó»ö ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÀÓ»óÀû ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÄÚÀÏ µðÀÚÀÎ, È帧 Àüȯ ±â¼ú, »öÀü¼ú Àç·áÀÇ ¹ßÀüÀ¸·Î Ä¡·á ¹üÀ§¿Í ¾ÈÀü¼ºÀÌ È®´ëµÇ¾î ÀÌÀü¿¡´Â Ä¡·áÇÒ ¼ö ¾ø¾ú´ø ´õ º¹ÀâÇÑ º´º¯À» Ä¡·áÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

½Å°æ°ú¿¡¼­ Ç÷°ü ³» Ä¡·á¿¡ ´ëÇÑ ½Å·Ú°¡ ³ô¾ÆÁü¿¡ µû¶ó ´õ ³ªÀº ¿µ»ó Áø´Ü ¹× Ž»ö µµ±¸°¡ µÞ¹ÞħµÇ¾î °³º¹ ½Å°æ¿Ü°ú ¼ö¼ú¿¡¼­ Ç÷°ü ³» Ä¡·á·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. ½Å°æÁßÀç¼ú¿¡ ´ëÇÑ ÀÇ»çÀÇ Àü¹® Áö½Ä°ú ±³À°ÀÌ Çâ»óµÇ¸é¼­ ä¿ëÀÌ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿ø°ú ³úÁ¹Áß ¼¾ÅÍ´Â Áõ°¡ÇÏ´Â ½Ã¼ú ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ Ã·´Ü ÀÎÅͺ¥¼Ç ½ºÀ§Æ®¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ °á°ú °³¼±°ú ȸº¹ ½Ã°£ ´ÜÃàÀ¸·Î ÀÎÇØ »öÀü¼úÀº ÀÇ»ç¿Í ȯÀÚ ¸ðµÎ¿¡°Ô ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ½Å°æÇ÷°ü »öÀü¼ú ÀåºñÀÇ Ã¤Åðú ±â¼ú Çõ½ÅÀÇ ²ÙÁØÇÑ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(»öÀü ÄÚÀÏ, ¾×ü »öÀü ½Ã½ºÅÛ, À¯·Î Àüȯ ½ºÅÙÆ®, µ¿¸Æ·ù Ŭ¸³ »öÀü, ±âŸ »öÀü ±â±â), Ä¡·á(ÇãÇ÷¼º ³úÁ¹Áß ¼Ö·ç¼Ç Ä¡·á, ÃâÇ÷¼º ³úÁ¹Áß ¼Ö·ç¼Ç Ä¡·á), ÀûÀÀÁõ(³úµ¿¸Æ·ù ÀûÀÀÁõ, µ¿Á¤¸Æ±âÇü ÀûÀÀÁõ, ±âŸ ÀûÀÀÁõ), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, Àü¹® Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Embolization Devices for Neurology Market to Reach US$1.8 Billion by 2030

The global market for Embolization Devices for Neurology estimated at US$1.6 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Embolization Coils, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$599.5 Million by the end of the analysis period. Growth in the Liquid Embolic System segment is estimated at 1.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$424.4 Million While China is Forecast to Grow at 4.9% CAGR

The Embolization Devices for Neurology market in the U.S. is estimated at US$424.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$348.7 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Embolization Devices for Neurology Market - Key Trends & Drivers Summarized

How Are Embolization Devices Revolutionizing Neurological Interventions?

Embolization devices are playing a crucial role in treating complex neurological conditions such as brain aneurysms, arteriovenous malformations (AVMs), and tumors. These devices work by intentionally blocking abnormal blood vessels or reducing blood flow to affected areas, minimizing the risk of rupture or hemorrhage. In neurology, embolization is often used as a pre-surgical adjunct or as a standalone minimally invasive procedure. Technological advances have made embolization a viable, targeted solution that avoids the risks associated with open neurosurgery.

The increasing prevalence of cerebral aneurysms and stroke cases is leading to a rise in neurovascular embolization procedures. Advances in imaging, catheterization, and microcoil design have enabled physicians to treat previously inoperable vascular abnormalities with greater precision. Use of real-time navigation and smaller, more flexible delivery systems has improved patient outcomes and reduced complication rates. Embolization has also become the preferred method for managing certain vascular tumors and hemorrhagic stroke conditions, especially when surgical access is difficult.

What Innovations Are Enhancing Precision and Efficacy of Embolization Devices?

Material innovations in embolic agents, such as hydrogel-coated coils, detachable balloons, and liquid embolics, are increasing the accuracy and permanence of vessel occlusion. These materials are designed to conform to complex vascular geometries while maintaining biocompatibility and reducing the risk of migration or recanalization. Some newer devices allow for controlled detachment or expansion, enabling more precise deployment in sensitive brain regions. The rise of flow-diverting stents and intrasaccular flow disruptors has expanded the therapeutic range of embolization beyond conventional coil-based treatments.

Improvements in catheter technology are enabling more stable and trackable navigation through tortuous cerebral vessels. Steerable microcatheters, coated guidewires, and low-profile delivery systems have significantly improved device placement accuracy and procedural efficiency. These innovations reduce the risk of vessel trauma and increase procedural success rates, especially in complex or deep-seated neurovascular cases. As imaging systems continue to improve, integration with embolization procedures is enabling better planning, intra-operative assessment, and post-treatment follow-up.

Which Healthcare Settings and Neurological Conditions Are Driving Demand?

Tertiary care hospitals and stroke centers remain the primary settings for neurovascular embolization procedures, supported by access to advanced imaging, specialized neuro-intervention teams, and intensive care infrastructure. Conditions most commonly treated include intracranial aneurysms, AVMs, and hemorrhagic strokes. Embolization is also used to manage vascular tumors such as meningiomas and to reduce intraoperative bleeding during neurosurgery. As awareness of non-invasive treatment options grows, demand for these procedures is increasing even in secondary care settings equipped with basic interventional radiology.

The expanding use of embolization in emergency neurology, particularly in acute hemorrhagic events, is increasing the need for rapid, efficient device systems. Tele-neurology and stroke referral networks are helping smaller centers connect with advanced intervention units, further boosting procedure volumes. Additionally, as diagnostic screening improves and detection rates of incidental aneurysms rise, more patients are being referred for preemptive embolization. This growing procedural volume across both emergent and elective settings is strengthening the market's growth base.

What Is Driving Growth in the Embolization Devices for Neurology Market?

Growth in the embolization devices for neurology market is driven by several factors related to disease prevalence, device precision, and minimally invasive treatment demand. Rising incidence of brain aneurysms, AVMs, and hemorrhagic strokes is increasing the clinical need for targeted vascular occlusion solutions. Advances in coil design, flow-diversion technology, and embolic materials are expanding the scope and safety of procedures, enabling treatment of more complex and previously untreatable lesions.

Increased reliance on endovascular procedures in neurology, supported by better imaging and navigation tools, is encouraging the shift away from open neurosurgery. Growing physician expertise and training in neuro-intervention is further enabling adoption. Additionally, hospitals and stroke centers are investing in advanced interventional suites to meet rising procedural demand. With improved patient outcomes and reduced recovery times, embolization is gaining broader acceptance among both practitioners and patients. These factors are reinforcing steady growth in adoption and innovation in neurovascular embolization devices.

SCOPE OF STUDY:

The report analyzes the Embolization Devices for Neurology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Embolization Coils, Liquid Embolic System, Flow Diversion Stents, Aneurysm Clips Embolization, Other Embolization Devices); Treatment (Ischemic Stroke Solutions Treatment, Hemorrhagic Stroke Solutions Treatment); Indication (Brain Aneurysms Indication, Arteriovenous Malformation Indication, Other Indications); End-User (Hospitals End-User, Ambulatory Surgery Centers End-User, Specialty Clinics End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â